* AbbVie’s investigational HCV regimen receives U.S. FDA
Breakthrough Therapy Designation
Source text for Eikon:
Further company coverage:
;))
The post BRIEF-Abbvie’s investigational HCV regimen receives FDA Breakthrough Therapy Designation appeared first on NASDAQ.